A one day symposium bringing together investigators, researchers, and clinicians from National Institute of Allergy and Infectious Diseases (NIAID) and Children’s National Hospital as well as other interested participants from outside institutions, to discuss the creation, progress, and evolution of this first-of-its-kind collaboration between the NIAID at the National Institutes of Health and Children's National, a pediatric academic medical center. This year, the event will highlight the current COVID-19 and MIS-C pandemic, with a specific focus on the pediatric population. Dr. Anthony Fauci, Director of NIAID, will provide an overview on the infectious disease, and leading experts from Children’s National, NIAID, and other institutions will share the novel research and science being done to address this worldwide issue.
Questions? Contact us at CN-NIAIDPartnership@childrensnational.org
3rd Annual children's national-niaid Virtual symposium
This virtual symposium is free to attend and participants are required to register. Now closed.
AGENDA: September 29, 2020
9:00 - 10:00 am ET.....Opening with Leadership
Moderator: Lisa M. Guay-Woodford, MD (Children's National)
Welcome: Kurt Newman, MD (Children's National)
Overview of SARS-CoV-2: Anthony S. Fauci, MD (NIAID)
Role of NCATS in the the SARS-CoV-2 Response: Christopher P. Austin, MD (NCATS)
10:00 - 12:10 pm ET...Immunobiology and Host Genomics
Moderator: Catherine Bollard, MD, MBChB (Children's National)
Humoral Immune Response: Jeffrey I. Cohen, MD (NIAID)
Cellular Response (T and NK Cells): Michael Keller, MD (Children's National)
Immunopathogenesis of MIS-C: Sarah E. Henrickson, MD, PhD (CHOP)*
Genomic Factors in SARS-CoV-2: Helen Su, MD, PhD (NIAID)
12:10 - 12:40 pm ET...Break
12:40 - 2:10 pm ET.....Epidemiology and Clinical Manifestations
Moderator: Luigi Notarangelo, MD (NIAID)
Health Disparities and SARS-CoV-2: Akilah Jefferson Shah, MD, MSc (UAMS)
Clinical Spectrum of SARS-CoV-2, Implication for Schools Reopening: Dan M. Cooper, M.D. (UC Irvine)
MIS-C and Post SARS-CoV-2 Monitoring in Children: Roberta DeBiasi, MD, MS (Children's National)
Post SARS-CoV-2 Monitoring in Adults: Michael C. Sneller, MD (NIAID)
2:20 - 3:50 pm ET.......Treatment Strategies
Moderator: Richard Davey, MD (NIAID)
Overview of Vaccine Candidates: Peter Hotez, MD, PhD (Baylor)
Current State of Vaccine Clinical Trials: Julie Ledgerwood, DO (NIAID)
Ongoing Therapeutic Trials and Treatment Guidelines: Cliff Lane, M.D. (NIAID)
4:00 - 4:30 pm ET.......Closing Remarks
Moderator: Lisa M. Guay-Woodford, MD (Children's National)
SARS-CoV-2 What Comes Next – Societal/Economic Impact: Ezekiel Emanuel, MD, PhD (UPenn)
All times listed are in the Eastern timezone.
This schedule is subject to change.
View the online brochure
about the partnership
In 2017, The National Institute of Allergy and Infectious Diseases (NIAID) and Children’s National Hospital launched a clinical research partnership devoted to protecting and advancing the health of children with allergic, immunologic, auto-inflammatory, and infectious disease through collaborative research and education. This strategic and novel alliance is supported through the Clinical and Translational Science Institute at Children’s National (CTSI-CN). The partnership, co-led by H. Clifford Lane, M.D., Deputy Director for Clinical Research and Special Projects at NIAID, and Mark Batshaw, M.D., Executive Vice President and Chief Academic Officer at Children’s National, holds the mission to generate and apply knowledge to promote the prevention, diagnosis, treatment, and cure of these childhood diseases through its work together.
For each area, designated investigators from each institution are collaborating to design and conduct clinical research studies that will advance prevention strategies, diagnoses, treatments, and cures for the diverse range of pediatric diseases involving the immune system. Many of these studies will include children at high risk for complications related to their underlying disease or to experimental therapeutics and diagnostic tests they receive. Research participants will have the opportunity to be seen at both Children’s National and the NIH Clinical Center in Bethesda, Maryland. Together, the two institutions provide comprehensive, state-of-the-art pediatric clinical support, infrastructure, and research capacity. These resources protect the safety of children, ensure that they receive the highest quality of care, and offer them the opportunity to participate in cutting-edge clinical research. In addition, the partnership established joint training opportunities for physician-scientists interested in caring for these children while developing their research expertise in pediatric immunology, allergic, and infectious diseases.
The collaboration is supported through an NIAID supplement to the Clinical and Translational Science Institute at Children's National, which is funded by a Clinical and Translational Science Award from NIH’s National Center for Advancing Translational Sciences to Children’s National Hospital and The George Washington University.
EXECUTIVE STEERING COMMITTEE:
Children’s National Hospital - Children’s National, based in Washington, D.C., has served the nation’s children since 1870. Children’s National is one of the nation’s Top 5 pediatric hospitals and, for a second straight year, is ranked No. 1 in newborn care, as well as ranked in all specialties evaluated by U.S. News & World Report. It has been designated two times as a Magnet® hospital, a designation given to hospitals that demonstrate the highest standards of nursing and patient care delivery. This pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty outpatient centers in the D.C. Metropolitan area, including the Maryland suburbs and Northern Virginia. Home to the Children’s Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National is the seventh-highest NIH-funded pediatric institution in the nation. Children’s National is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels.
National Institute of Allergy and Infectious Diseases (NIAID) - NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. Visit NIAID for news releases, fact sheets and other NIAID-related materials.
September 18, 2018: Inaugural CN-NIAID Symposium
November 8, 2019: 2nd CN-NIAID Symposium